In its fourth quarter and full year financial results statement, Ireland-incorporated Shire (LSE: SHP) posted stronger-than-expected sales and profits today, resulting in a 2.5% jump in the company’s share price.
The company missed analysts’ expectations in the third quarter of last year, largely due to the absorption of costs related to its $32 billion takeover of American biotech firm Baxalta.
In the fourth quarter of 2016 Shire achieved revenues of $3.8 billion, up 122% from the year earlier, following generally accepted accounting principles (GAAP). Net income was $457 million, an increase of 63%. Earnings per share (EPS) stood at $1.51.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze